Drug
Rdc 0313
Rdc 0313: highest development phase Phase 2, developed by Alkermes. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Alkermes
Trials
| Drug | Phase | Indication |
|---|---|---|
| RDC-0313 (ALKS 33) NCT01098435 | Phase 2 | Binge Eating Disorder |
| RDC-0313 NCT00800319 | Phase 1 | Alcohol Dependence |
Latest
No recent events.
Follow Rdc 0313 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.